Close Menu

Oxford Immunotec

Oxford Immunotec said that a decrease in revenues for its US business was partly driven by the impact of planned inventory destocking by Quest Diagnostics.

National TB control programs may now order the T-spot.TB, a blood test for TB screening, through the Stop TB Partnership - GDF procurement mechanism.

Of the 28 companies in the index, 21 firms saw their stock prices increase throughout the first half of the year, while seven firms' share prices decreased.

Private equity firms KKR and Ampersand Capital have reportedly proposed acquiring Oxford Immunotec for around $15 per share in cash.

Asia revenue fell 22 percent year over year, primarily due to a slowdown of testing in China as a result of the COVID-19 pandemic, the company said.

News items for the in vitro diagnostics industry for the week of April 20, 2020. 

The firm said that since March, when it provided its full-year 2020 guidance, it has seen a significant decline in testing demand as a result of the COVID-19 pandemic.

Of the 28 companies in the 360 Index, six companies' share prices increased while the share values of 22 declined month over month.

Recent publications demonstrating the clinical utility of the CMV assay represent a step toward diversifying into different types of assays, the firm said.

The company said it continues to see the global tuberculosis market expanding, and it is investing in both commercial resources and R&D.

Pages